Cargando…

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation

Host immune responses are pivotal for the successful treatment of the leishmaniases, a spectrum of infections caused by Leishmania parasites. Previous studies speculated that augmenting cytokines associated with a type 1 T-helper cell (Th1) response is necessary to combat severe forms of leishmanias...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palić, Semra, Bhairosing, Patrick, Beijnen, Jos H., Dorlo, Thomas P. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591591/ https://www.ncbi.nlm.nih.gov/pubmed/31036692 http://dx.doi.org/10.1128/AAC.02507-18

Ejemplares similares

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
por: Palić, Semra, et al.
Publicado: (2020)

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis
por: Castro, María del Mar, et al.
Publicado: (2017)

Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine
por: Dorlo, Thomas P. C., et al.
Publicado: (2011)

No evidence for cardiotoxicity of miltefosine()
por: Dorlo, Thomas P.C.
Publicado: (2022)

Failure of Miltefosine Treatment for Visceral Leishmaniasis in Children and Men in South-East Asia
por: Ostyn, Bart, et al.
Publicado: (2014)

1662. Pushing the Dose: Miltefosine Treatment for a Supersized American with Cutaneous Leishmaniasis
por: Aronson, Naomi E, et al.
Publicado: (2019)

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection
por: Kip, A. E., et al.
Publicado: (2016)

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
por: Dorlo, Thomas P C, et al.
Publicado: (2017)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
por: Verrest, Luka, et al.
Publicado: (2023)

SUCCESSFUL TREATMENT OF MULTIFOCAL CUTANEOUS LEISHMANIASIS WITH MILTEFOSINE
por: Madke, Bhushan, et al.
Publicado: (2011)

Miltefosine Rescue Treatment for Visceral Leishmaniasis Relapse Patient
por: Bastola, Anup, et al.
Publicado: (2019)

Post-kala-azar Dermal Leishmaniasis Developing in Miltefosine-Treated Visceral Leishmaniasis
por: Koley, Sankha, et al.
Publicado: (2013)

Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis
por: Ferreira, Carolina, et al.
Publicado: (2020)

A Poor-Quality Generic Drug for the Treatment of Visceral Leishmaniasis: A Case Report and Appeal
por: Dorlo, Thomas P. C., et al.
Publicado: (2012)

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial
por: Mbui, Jane, et al.
Publicado: (2019)

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
por: Musa, Ahmed M, et al.
Publicado: (2022)

Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management
por: Sundar, Shyam, et al.
Publicado: (2007)

Lingual Leishmaniasis Presenting to Maxillofacial Surgery in UK with Successful Treatment with Miltefosine
por: Kassam, K., et al.
Publicado: (2013)

Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India
por: Patra, Pradyumna, et al.
Publicado: (2012)

Efficacy and Safety of Miltefosine in Treatment of Post-Kala-Azar Dermal Leishmaniasis
por: Sundar, Shyam, et al.
Publicado: (2015)

Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
por: Srivastava, Saumya, et al.
Publicado: (2017)

Miltefosine for the treatment of cutaneous leishmaniasis—A pilot study from Ethiopia
por: van Henten, Saskia, et al.
Publicado: (2021)

Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis
por: Iranpour, Sohrab, et al.
Publicado: (2019)

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis
por: Kip, Anke E., et al.
Publicado: (2018)

Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis
por: Proverbio, Daniela, et al.
Publicado: (2016)

Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil
por: dos Santos Nogueira, Fabio, et al.
Publicado: (2019)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2021)

A case of miltefosine responsive pleomorphic post kala-azar dermal leishmaniasis
por: Pal, Dipankar, et al.
Publicado: (2013)

Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients
por: OLLECH, Ayelet, et al.
Publicado: (2020)

Clinical and Laboratory Response of Domiciled Dogs with Visceral Leishmaniasis Treated with Miltefosine and Allopurinol
por: Vaz, Talita Pereira, et al.
Publicado: (2023)

Safety and Effectiveness of Miltefosine in Post–Kala-Azar Dermal Leishmaniasis: An Observational Study
por: Sundar, Shyam, et al.
Publicado: (2023)

Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis
por: Bhandari, Vasundhra, et al.
Publicado: (2012)

Resolution of Cutaneous Old World and New World Leishmaniasis after Oral Miltefosine Treatment
por: Tappe, Dennis, et al.
Publicado: (2010)

A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis
por: Carnielli, Juliana B.T., et al.
Publicado: (2018)

Comparison of cardiotoxicity between N-methyl-glucamine and miltefosine in the treatment of American cutaneous leishmaniasis()()
por: Barroso, Daniel Holanda, et al.
Publicado: (2021)

Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis
por: Melcon-Fernandez, Estela, et al.
Publicado: (2023)

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Omollo, Raymond, et al.
Publicado: (2011)

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study
por: Kip, Anke E, et al.
Publicado: (2021)

Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled Trial
por: Machado, Paulo R., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_aafs11fbtcl3744cb0sg7mju34